Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,465 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07612176RecruitingPhase 1
Testing NEOK001 drug for advanced solid tumors
This study tests a new cancer drug called NEOK001 that targets two proteins (B7-H3 and ROR1) found on certain tumor cells. The drug combines a cancer-fighting molecule with a toxic payload to kill cancer cells while sparing healthy tissue.
New York, New YorkAges 18 years+ - NCT07426055RecruitingPhase 2/Phase 3
Prostate cancer radiation boost comparison study
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06773507RecruitingPhase 1
Study of BC008-1A for advanced solid tumors
This trial tests a new drug called BC008-1A for people with advanced esophageal cancer or non-small cell lung cancer that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
TianjinAges 18 years+ - NCT04273061RecruitingPhase 2
Atezolizumab for tumors that look sensitive on DNA/RNA testing
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
Vancouver, British ColumbiaAges 18 years+ - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Newport Beach, CaliforniaAges 18 years+ - NCT05799274RecruitingPhase 1
Safety study of a new PET imaging drug for cancers
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
Princeton, New JerseyAges 18 years+ - NCT07426094RecruitingPhase 2/Phase 3
Boosting radiation for prostate cancer in lymph nodes
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT06613295Recruiting
Spine cancer trial: Surgery plus radiation vs radiation alone
This trial compares two treatments for cancer that has spread to the spine: surgery followed by precise radiation versus radiation alone. It aims to see if adding surgery improves pain, movement, and quality of life.
AalstAges 18 years+ - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05687136RecruitingPhase 1
Study two targeted drugs for solid tumors with DNA repair changes
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
Bethesda, MarylandAges 18 years+ - NCT06672523RecruitingPhase 1
Study of a new drug for advanced solid tumors with MTAP deletion
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
BudapestAges 18 years+ - NCT06410131RecruitingPhase 1
Safety study of FTL008.16 for advanced solid tumors
This trial tests an investigational drug called FTL008.16 for people with advanced solid tumors that may carry a protein called 5T4. The main goal is to see if the drug is safe and tolerable.
Beijing, Beijing MunicipalityAges 18–75 - NCT07712029RecruitingPhase 2
A new drug combo for EGFR positive advanced solid tumors
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07190833RecruitingPhase 1
Study of a cancer-killing virus injection for solid tumors
This early-phase trial tests a cancer-killing virus (OTS-412) that is injected directly into tumors. It is for people with solid tumors that have not responded to standard treatments, including immunotherapy. The goal is to see if the virus can shrink or control the injected tumors.
BusanAges 19 years+ - NCT06375564RecruitingPhase 1
A new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (177Lu-AB-3PRGD2) that targets a protein called integrin αvβ3 found on many solid tumors. It is for people whose cancer has not responded to or has come back after several standard treatments.
Xiamen, FujianAges 18–90 - NCT05541822RecruitingPhase 2
Study drug for lung cancer with specific c-MET changes
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
Lake City, FloridaAges 18 years+ - NCT06330064RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07492680RecruitingPhase 2
Study of BMS-986504 for solid tumors with MTAP deletion
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
San Francisco, CaliforniaAges 18 years+ - NCT05315700RecruitingPhase 1/Phase 2
ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Duarte, CaliforniaAges 18 years+ - NCT04871542Recruiting
Predicting risk of immune therapy side effects
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Anchorage, AlaskaAges 18 years+
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,465 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.